Cantor Fitzgerald Issues Positive Outlook for TLSI Earnings

Key Points

• Cantor Fitzgerald has raised its FY2025 earnings per share (EPS) estimate for TriSalus Life Sciences from ($0.90) to ($0.85), and forecasts FY2026 earnings at ($0.13) EPS.
• TriSalus Life Sciences reported a quarterly EPS of ($0.27), missing analysts' expectations, but achieved revenue of $11.21 million, exceeding estimates.
• Institutional investors have increased their positions in TriSalus Life Sciences, with Nantahala Capital Management acquiring $10.9 million worth of shares in Q2.

TriSalus Life Sciences, Inc. (NASDAQ:TLSI - Free Report) - Analysts at Cantor Fitzgerald lifted their FY2025 earnings per share (EPS) estimates for TriSalus Life Sciences in a note issued to investors on Wednesday, August 13th. Cantor Fitzgerald analyst R. Osborn now expects that the company will earn ($0.85) per share for the year, up from their prior forecast of ($0.90). The consensus estimate for TriSalus Life Sciences' current full-year earnings is ($1.55) per share. Cantor Fitzgerald also issued estimates for TriSalus Life Sciences' FY2026 earnings at ($0.13) EPS.

TriSalus Life Sciences Stock Up 10.1%

TLSI traded up $0.47 during trading on Friday, reaching $5.12. The stock had a trading volume of 105,013 shares, compared to its average volume of 62,920. The firm has a market capitalization of $193.74 million, a price-to-earnings ratio of -4.34 and a beta of 0.48. TriSalus Life Sciences has a 1-year low of $3.42 and a 1-year high of $5.88. The stock has a 50 day moving average of $4.75 and a two-hundred day moving average of $5.20.

TriSalus Life Sciences (NASDAQ:TLSI - Get Free Report) last released its earnings results on Tuesday, August 12th. The company reported ($0.27) earnings per share for the quarter, missing analysts' consensus estimates of ($0.22) by ($0.05). The business had revenue of $11.21 million during the quarter, compared to analysts' expectations of $10.69 million. TriSalus Life Sciences has set its FY 2025 guidance at EPS.

Institutional Investors Weigh In On TriSalus Life Sciences

Institutional investors have recently added to or reduced their stakes in the company. Nantahala Capital Management LLC acquired a new stake in shares of TriSalus Life Sciences during the 2nd quarter valued at $10,900,000. AWM Investment Company Inc. acquired a new stake in shares of TriSalus Life Sciences during the 2nd quarter valued at $6,812,000. Gilder Gagnon Howe & Co. LLC lifted its position in shares of TriSalus Life Sciences by 32.1% during the 2nd quarter. Gilder Gagnon Howe & Co. LLC now owns 1,092,975 shares of the company's stock valued at $5,957,000 after acquiring an additional 265,618 shares during the last quarter. Geode Capital Management LLC lifted its position in shares of TriSalus Life Sciences by 107.4% during the 2nd quarter. Geode Capital Management LLC now owns 455,051 shares of the company's stock valued at $2,480,000 after acquiring an additional 235,627 shares during the last quarter. Finally, Bank of America Corp DE lifted its position in shares of TriSalus Life Sciences by 120,471.6% during the 4th quarter. Bank of America Corp DE now owns 178,446 shares of the company's stock valued at $894,000 after acquiring an additional 178,298 shares during the last quarter. 2.58% of the stock is currently owned by institutional investors and hedge funds.

TriSalus Life Sciences Company Profile

TriSalus Life Sciences, Inc, a medical technology company, researches, develops, and sells drug delivery technologies and immune-oncology therapeutics for the treatment of liver and pancreatic cancer. The company offers Pressure Enabled Drug Delivery infusion systems, such as the TriNav infusion system, which is used in transarterial radioembolization and chemoembolization procedures for patients with liver cancer and metastases; and the Pancreatic Retrograde Venous Infusion device, which is in Phase 1 clinical trial, for locally advanced pancreatic cancer.